About Us

We are a fully-integrated pharmaceutical company, with development, manufacturing and sales capabilities, serving a regional population of 100 million patients and are expanding to reach even more patients globally.

Company Overview

With over 15 years track record of successful manufacturing and distribution of pharmaceutical products for local and regional customers, KSP is undergoing the next stage of its impressive journey. Following the recent acquisition of a majority stake in KSP by a large local conglomerate, KSP now has the financial backing and investor support to continue its growth. This investment is both in manufacturing lines, manufacturing buildings, acquisitions and partnerships to develop the product and portfolio range, from its current level of over 120 products, to enable the provision of a wider and broader range of high-quality medicines, throughout the Middle-East and further afield.

KSP Corporate History Timeline

KSP Establishment
KSP Re-Establishment
March 1996
Launching date of the LVP line
Entering Bahrain Market
February 1998
Panadrex Registration
Entering Oman Market
Entering KSA Market
Entering Qatar Market
January 2001
Fludrex Registration
March 2001
Minisec Registration
Entering UAE Market
Entering Jordan Market
Sep 2014
Paracetamol IV Registration
Entering Sudan Market
Acquisition by Mezzan Holding Holding Co.
October 2019
Kuwait scientific Office
April 2020
KSA scientific office
August 2020
UAE scientific office